Jazz Pharmaceuticals’ (JAZZ) “Overweight” Rating Reaffirmed at Piper Sandler

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “overweight” rating restated by stock analysts at Piper Sandler in a research note issued to investors on Thursday,Benzinga reports. They presently have a $163.00 target price on the specialty pharmaceutical company’s stock. Piper Sandler’s price objective indicates a potential upside of 30.58% from the stock’s current price.

Several other equities analysts have also recently issued reports on JAZZ. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $140.00 to $175.00 in a report on Thursday. Robert W. Baird raised their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, TD Cowen dropped their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $177.00.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded up $4.11 during trading hours on Thursday, hitting $124.83. 390,034 shares of the company’s stock were exchanged, compared to its average volume of 666,297. The stock’s 50-day moving average is $116.81 and its 200-day moving average is $111.91. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $7.55 billion, a price-to-earnings ratio of 17.63, a price-to-earnings-growth ratio of 1.04 and a beta of 0.57. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $134.17.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,753 shares of company stock worth $816,289. 4.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares in the last quarter. GAMMA Investing LLC increased its holdings in Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 121 shares in the last quarter. Arizona State Retirement System increased its holdings in Jazz Pharmaceuticals by 0.8% in the 2nd quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock worth $1,770,000 after purchasing an additional 130 shares in the last quarter. Coldstream Capital Management Inc. increased its holdings in Jazz Pharmaceuticals by 7.7% in the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock worth $259,000 after purchasing an additional 165 shares in the last quarter. Finally, Itau Unibanco Holding S.A. increased its holdings in Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 172 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.